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ABSTRACT 
The field of chronobiology and chronotherapy in 
medicine is in its relative infancy. However, important 
knowledge has been gained so as to better understand 
both the pathophysiology of diseases and the corre-
sponding therapeutic interventions. Asthma is one of 
the disease entities that has been studied in detail in 
regard to both time related alterations in pathophysiol-
ogy and treatment. This article reviews the nocturnal 
worsening of asthma.
Key words: chronobiology, chronotherapy, nocturnal 
asthma, pathophysiology.
INTRODUCTION 
Asthma is a disease particularly suited to a discussion of 
chronobiology and chronotherapy because the pattern of 
the disease often changes from the waking to the sleep-
ing state. Dr John Floyer describing his own asthma in 
1698 wrote, 'I have observed the fit always to happen 
after sleep in the night, when the nerves are filled with 
windy spirits and the heat of the bed has rarefied the spir-
its and humours.'1 Dr Floyer is giving us an insight into 
what our asthma patients experience at night. DrTurner-
Warwick demonstrated in a very large population study of 
almost 8000 asthmatic outpatients that 39% had symp-
toms of asthma every night, 64% at least three nights per 
week and 74% at least one night per week.2 Thus, the 
asthmatic patient who appears stable during the daytime 
hours may in fact have marked worsening of asthma at 
night.
 Figure 1 schematically shows the circadian rhythm 
change in lung function in both normal subjects and asth-
matic patients.3 Even in normal subjects there is a day-
to-day change in lung function. The best lung function 
occurs around 4pm and the worst lung function approx-
imately 4am with about an 8% change in the normal 
population. The asthmatic patients, however, start with a 
lower lung function level, but independent of medications 
still have the highest peak flow rates at approximately 
4pm and the lowest at approximately 4am. The asth-
matic population, however, can have much more dra-
matic overnight decrements in lung function than the 
normal population. 
 Bronchial hyperresponsiveness has been evaluated 
between 4pm and 4am in two asthmatic groups.4 One 
group was an asthmatic control population, and the 
other had nocturnal asthma. As can be seen in Fig. 2,
Fig. 1 Peak expiratory flow rate (PEFR) and forced expiratory 
volume in 1 second (FEV1) are schematically shown for normal 
subjects and asthmatic patients. For both groups, the peak lung 
function occurs at approximately 4pm (1600h) and nadir lung 
function at 4am (0400h). (Reprinted with permission from 
Ref. 49.)
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Fig. 2 Bronchial hyperresponsiveness increases by approxi-
mately two-fold from 4pm (1600h) to 4am (0400h) in a 
group of asthmatic subjects who have small alterations in their 
FEV1 (control group) and by eight-fold in the nocturnal asthma 
group. (Drawn from data from Ref. 50.)
Fig. 3 Airway resistance (Rla) in six asthmatic patients progres-
sively increases from midnight (0000h) to 6am (0600h) inde-
pe den†ot sleep (□), but sleep itselt has a profound effect on
increased airway resistonce (●). (Reprinted With permission
from Ref. 4.)
Fig. 4 The complex interactions between various factors leading to the nocturnal worsening of asthma. Epi, epinephrine; SaO2' 
oxygen saturation. (Reprinted with permission from Ref. 49.)
even the asthma control population from 4pm to 4am 
had a worsening of bronchial reactivity. However, the 
nocturnal asthma group had a much greater increase in 
bronchial reactivity during the night.
 Does sleep itself alter the asthma rate? As shown in 
Fig. 3 there was a progressive increase in airway resis-
tance from midnight until 6am, independent of sleep. 
Sleep itself produces a further worsening of lung function
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(increasing in airway resistance).5 This worsening of air-
way function overnight is not caused by a single process. 
Although we do not know all the interactions involved, 
what is becoming evident is that there is a complex inter-
action of many factors (Fig. 4).
MECHANISMS OF NOCTURNAL CHANGES IN 
AIRWAY FUNCTION 
Neurohormonal changes 
Several neurohormones vary in a circadian fashion and 
are thought to contribute to the overnight fall in lung 
function. Cortisol is known to vary in a circadian fashion, 
with peak levels occurring upon awakening and trough 
levels around midnight.6 These changes are seen in both 
asthmatic and non-asthmatic individuals and thus alone 
are not felt to be responsible for the exaaaerated over-
night fall in peak expiratory flow rate (PEFR) seen in asth-
matics. However, the decreased levels at night certainly 
contribute to the nocturnal asthma process as cortisol is 
thought to exert an anti-inflammatory effect upon the 
chronically inflamed airways of asthmatics. 
 Epinephrine also varies in a circadian fashion, with 
peak levels during the afternoon hours and trough levels 
during the early morning hours.6 Patients with nocturnal 
asthma who were infused with physiologic doses of epi-
nephrine lessened but did not abolish their overnight 
decline in PEFR.6 Although epinephrine varies in a circa-
dian fashion in both asthmatic and non-asthmatic sub-
jects, asthmatics may experience bronchoconstriction due 
to decreased responsiveness to epinephrine. For example,
a reduced density of β-adrenergic receptors has been
noted on circulating leukocytes of asthmatic subjects.'-8 
This down-regulation of receptors may represent previous
β-2 agonist therapy, but a reduced density of receptors
has also been reported on untreated asthmatics.9 Epi-
nephrine also relaxes airway smooth muscle and inhibits 
leakage of histamine and other mediators from sensitized 
mast cells. Thus, circadian changes in circulating epi-
nephrine may promote asthma at night both by reducing 
bronchodilatation and by contributing to a 'permissive' 
release of spasmogenic mediators from mast cells.
Beta-2 adrenergic receptors 
Both the receptor density (number) and the physiologic 
response to isoproterenol decrease at 4am in patients 
with nocturnal asthma.10 In asthmatics without worsening
of lung function at night or in normal individuals this cir-
radian alteration in β-2 receptors does not occur. These
differences appear to be related to a genetic polymor-
phism. Those individuals with nocturnal asthma have a 
significantly higher genetic make-up for the Gly-16 poly-
morphism of the β-2 adrenergic receptor, which is asso-
dated with down-regulation of the receptor.11
Cholinergic tone 
There is evidence to suggest that cholinergic or vagal 
tone is increased at night, thus contributing to the circa-
dian change in airway function. Morrison et al. adminis-
tered atropine intravenously to subjects with nocturnal 
asthma and found improvement in the 4am PEFR as
compared with a placebo.12 Kallenbach et al. studied the 
heart rate variations induced by deep breathing, Valsalva 
maneuver and standing from the recumbent position in 
asthmatic and non-asthmatic subjects.13 The asthmatic 
subjects had evidence of enhanced parasympathetic 
neural drive to the sinoatrial node consistent with 
increased parasympathetic activity, both during the day 
and night.
Plasm  cyclic adenosine monophosphate 
Plasma cyclic adenosine monophosphate (CAMP) exhibits 
a prominent high amplitude circadian rhythm with the 
highest levels at 4pm and the lowest at 4am, correlating
to the time of the lowest airway patency.6 The pattern is 
similar in both asthmatics and non-asthmatics, although 
the 24-hour mean tends to be somewhat greater in non-
asthmatics. Changes in plasma CAMP over the day and 
night probably reflect epinephrine-mediated activation of 
tissue adenyl cyclase.
Inflammatory cells and mediators 
Asthma appears to be a disease at least partially asso-
ciated with and modulated by inflammation. The inflam-
matory cell most characteristic of asthma remains the 
eosinophil,14 but contributions by macrophages, lympho-
cytes and possibly neutrophils remain the focus of many 
current investigations.
 From a chronobiologic perspective, Martin et al. have 
implicated eosinophils in the pathogenesis of nocturnal 
worsening of asthma by showing that asthmatics who are 
prone to nocturnal worsening have increased recruitment 
f osi ophils into their 4am bronchoalveolar lavage
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(BAL) fluid.15 This phenomenon is not seen in asthmatics 
without nocturnal worsening. 
 Circadian variation in blood eosinophil numbers has 
been demonstrated in asthmatics with a nadir at 10am 
and a maximum concentration near midnight.16 In that 
study, the 4pm and 4am counts were similar. This raises 
the possibility that peak blood eosinophil levels precede 
the increase of eosinophils seen in the airway. Conse-
quently, nocturnal worsening of asthma and circadian 
eosinophil trafficking into the lung appear to be related 
events.
 In addition to eosinophils, T lymphocytes are com-
monly found in the inflammatory milieu associated with 
severe asthma.17-19 The observations that blood T lym-
phocytes expressing the interleukin-2 receptor are ele-
vated in patients with acute, severe asthma, that T 
lymphocytes appear to emigrate from the circulatory pool 
into the lung following allergen challenge, and that mod-
els of eosinophilic inflammation are T-lymphocyte-medi-
ated suggests a role for lymphocytes in asthmatic 
inflammation.20 In asthmatics prone to nocturnal worsen-
ing, elevated BAL lymphocyte numbers have been 
demonstrated at 4am, the typical nadir of overnight lung
function.15 These observations support a role for lympho-
cytes in the pathogenesis of nocturnal asthma and sug-
gest a situation in which biologic rhythms may influence 
inflammatory events by altering an available pool of cir-
culating cells. Many mediators of bronchoconstriction 
have been shown to be elevated at night.
Exogenous factors 
Exogenous environmental factors can be important trig-
gering factors in the overnight decrement in lung function. 
Exposure to specific agents during the daytime is not only 
capable of provoking acute asthma, but also in producing 
a late asthmatic response that may result in nocturnal 
symptoms. In addition, the late asthmatic response has 
been found to be more profound and more prolonged in 
subjects challenged with antigen later in the day.21
Gastroesophageal reflux 
Although gastroesophageal reflux disease (GERD) is 
often discussed as a possible trigger for nocturnal bron-
chospasm, Tan et al. studied subjects with nocturnal 
asthma and GERD using pH probes and found no corre-
lation with increased overnight acid secretion and exac-
erbation of nocturnal bronchospasm.22 However, during 
a trial of an H2 antagonist in patients with both sympto-
matic GERD and nocturnal bronchospasm, a small sig-
nificant improvement in asthma symptoms was seen.23 
There was no change in morning PEFR. Thus, asthmatics 
with GERD should certainly be treated for their symptoms, 
but at present GERD does not appear to be a significant 
trigger of nocturnal bronchospasm.
CHRoNoTHEPEuTIc RA NTERVENTIONS IN 
ASTHMA 
With understanding of the chronobiology of asthma, we 
now see the importance of assessing the disease manifes-
tations, as they differ in the day and in the night. For those 
patients with marked nocturnal worsening of disease, 
pharmacotherapy must be altered to specifically tailor 
treatment for sleep hours. Even in the treatment of 
asthma that does not worsen at night, there may be opti-
mal timing of medication use to provide maximal efficacy 
and minimal toxicity. These issues will be addressed in the 
following discussion of the many pharmacologic agents 
now available for the treatment of asthma.
Corticosteroids 
Although numerous investigators have demonstrated that 
corticosteroid side-effects, such as adrenal suppression, 
are influenced by the dosing schedule as well as the 
dosage, the alternative approach of evaluating differ-
ences in corticosteroid efficacy by varying dose schedules 
has received less attention. Recognition that cortico-
steroid administration should be adjusted to achieve the 
most favorable balance between time-dependent varia-
tions in both efficacy and adversity is central to therapeu-
tic success.
  Reinberg et al. have a sustained interest in the time-
d pendent pharmacology of corticosteroids with respect 
to efficacy in managing asthma.24-27 Their studies have 
shown repeatedly the importance of time-related dosing 
with afternoon superiority in efficacy and no increase in 
side effects.
 To better clarify the contribution of the timing of 
corticosteroids to their ability to block circadian recruit-
ment of inflammatory cells into the lung and attenuate the 
nocturnal worsening of asthma, Beam et al. evaluated 
the sponse of blood eosinophil counts, BAL cytology, 
and overnight pulmonary function to a single, variably
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timed dose of prednisone.28 Seven asthmatic males with 
stable, well-controlled daytime asthma but persistent noc-
turnal worsening of spirometry were treated in a double-
blind placebo controlled design with a single 50mg dose 
of prednisone at dose times of 8am or 3pm or 8pm. 
Compared with the placebo, a single prednisone dose at 
3pm resulted in a reduction in the overnight percent fall 
in FEV1 and improvement in the inflammatory environ-
ment of the airways. In contrast, neither the 8 am nor the 
8pm prednisone dose when compared to placebo 
resulted in overnight spirometric improvement. 
In a study by Pincus et al. using inhaled steroids in a 
general asthma population, the 3pm dose timing effect 
was again evaluated.29 In that study, a single dose of
800μg of triamcinolone acetonide at 3pm was com-
pared tothe sametotal dose divided into 200μg given at
7am, noon, 7pm and 10pm. The group receiving the 
3pm inhaled steroid had improvement equivalent to that 
seen in the four times a day dosing group as measured by 
FEY1, morning and evening peak flow rates, and the use
of β-agonists. Previous studies examining dosage sched-
ule effect had already demonstrated that four-times-a-
day scheduling was the most consistently effective 
treatment schedule for inhaled steroids in asthmatic 
patients.30,31 Therefore, the finding that 3pm dosing for 
inhaled steroids was as effective as four times daily dos-
ing again provided evidence for the value of the 3pm 
dosage time in asthma therapy for corticosteroids. In 
addition, the group receiving 3pm treatment had no 
greater evidence of adrenal suppression or drug toxicity 
than the four-times-a-day treatment group.
 With evidence pointing to the importance of mid-after-
noon steroid dosing in asthma, the question of possible 
time-dependent adverse effects must be addressed. Well-
controlled studies have shown between 8am and 4pm, 
adrenal suppression with oral steroids is equivalent.32,33 
After 6pm and approaching 11pm is where adrenal 
suppression is the highest.32,34
Theophylline 
Many studies have now shown that dosing theophylline 
on a time-related basis is superior to the standard home-
ostatic dosing.35-38 That is, a relatively constant serum 
theophylline concentration over a 24-hour period is not 
as beneficial to the asthmatic individual as having peaks 
and troughs at the appropriate times of day. Martin et al. 
have shown that giving a twice-daily theophylline prepa-
ration, which produced relatively constant therapeutic
serum theophylline concentrations in the 11-14μg/mL
range, was not as effective in treating patients as a single-
daily preparation giving peaks of approximately 15-16 
mg/mL during the sleep-related hours and falling to as
low as 7-8μg/mL during the daytime hours.36 Com-
paring the FEV, measured every 2h during the daytime 
showed no difference. Again, this is due to the fact that 
during the daytime lung function, independent of medi-
cation, is at its best. Thus, to produce a given amount of 
bronchodilatation during the daytime, it does not take 
as high a drug level. Conversely, the improvement in 
the overnight decrement in lung function indeed 
d pended upon a higher serum theophylline concentra-
tion. Although the traditional way of giving theophylline 
produced a therapeutic nocturnal theophylline level,
there still was approximately a 28% fall in the FEV1 
overnight. With the higher serum theophylline con-
centration, the overnight decrement in FEV1 was only 
approximately 9%. 
  D'Alonzo et al. also demonstrated that time-related 
drug levels resulted in improvements of lung function.39 
These investigators looked at the effects over a 4-hour 
block of time from 2 to 6pm compared with 2 to 6am. In 
the afternoon they did not find a significant correlation of 
increasing serum theophylline concentrations with 
improvement in FEV1. This is similar to many other day-
time studies.36,38 However, looking at the 4-hour time 
block from 2 to 6am these investigators did find a pro-
gressive and significant increase in the FEV1 as the serum 
theophylline concentration was increasing. 
 Do theophyllines grossly disturb sleep? In the study by 
Martin et al. no significant difference was found between 
the higher and lower serum theophylline concentrations 
in regard to polysomnographic evaluation.36 The sleep 
latency (how long it takes an individual to go to sleep), 
the sleep efficiency (how well the patient sleeps), and the 
different sleep stages were not different between the two 
levels of theophylline. Of interest, with the higher serum 
theophylline concentration there was a marked reduction
in the amount of oxygen desaturation that occurred over-
night. Other studies of normal subjects have shown mini-
mal to no adverse effects of theophylline on sleep 
characteristics or daytime function,40,41 
 Thus, if theophylline is selected to be used as therapy in 
an sthmatic individual, higher levels should be obtained
during sleep (15μg/mL) and then the level can fall dur-
ing the daytime (7-9μg/mL).
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Slow-release β-adrenergic agonist therapy
Slow-release (SR) β-agonist tablets can significantly mod-
erate the morning dip in airway patency in asthmatic 
patients. In this regard, Postma et al. showed the advan-
tage of an unequal morning-evening treatment schedule 
(one-third daily dose at 8am and two-thirds at 8pm) for 
terbutaline.42 Despite the potential of this class of med-
ication, only a limited number of published investigations 
have addressed the utility of these drugs as an evening 
chronotherapy for alleviating nocturnal asthma. Moore-
Gillon evaluated the efficacy of an 8mg dose of albu-
terol in patients with nocturnal symptoms.43 Evening SR 
albuterol resulted in a significant increase in morning
PEFR and a decrease in wheezing and shortness of breath 
as compared with placebo.43 Furthermore, evening SR 
albuterol dosing was associated with significantly 
reduced daytime symptom scores of wheeze, shortness of 
breath and sputum production.43,44 Finally, the recently 
released long-acting inhaled B-2 agonist salmeterol has 
shown promise in improving the overnight decrement in 
lung function. In a 12 month study of moderate asth-
matics comparing short-acting inhaled salbutamol with 
long-acting salmeterol, the patient group receiving the
long-acting salmeterol showed greater improvement in 
lung function, symptom scores, nocturnal awakening, 
and use of additional bronchodilator.45 There was no evi-
dence for deterioration of asthma control during the 
long-term administration of this medication. This was of 
particular importance in view of the concern that long-
term use of regular β-agonists might decrease asthma
control.46 Another study carried out over 3 months con-
firmed the greater efficacy of long-acting salmeterol over 
salbutamol, especially for nocturnal worsening of 
asthma.47 In addition, no increased adverse effects or 
decreased asthma control were seen with the salmeterol 
group. 
 Fitzpatrick et al. evaluated a dose comparison of 50
and 100μg of salmeterol inhaled twice daily.48 Both
doses were found to produce similar improvement in
nocturnal asthma lung function but only the 50μg dose
objectivity improved sleep quality; the patients spent less 
time awake or in light sleep and more time in stage 4 
slow wave sleep compared with the placebo. It appears 
that the higher dose of salmeterol may have had a stimu-
latory effect on the central nervous system.
Therefore, it appears that the longer acting inhaled β-
agonists are suited for use in patients with nocturnal
worsening of asthma. Further studies on optimal dosing 
and the risk of tolerance to the beneficial effects of these 
medications are still needed.
Anticholinergics
Because vagal tone increases in all of us at night, this is 
ne possible mechanism of circadian alteration in lung 
function. Many studies have not demonstrated a benefit 
of vagalytics, such as atropine or ipratropium bromide, 
but these studies have all been done during the daytime 
(unpubl. data). Morrison et al. have shown that one can 
i deed see marked bronchodilatation depending on the 
time of day the anticholinergic medication is given.12,49 
Th t is, during the daytime hours they found only slight 
bronchodilatory effects from atropine. However, at 4am
there was a marked improvement in PEFR to approxi-
mately the daytime levels. This strongly supports the need 
for us to understand when and how to use certain med-
ications. The problem with any vagalytic medication is 
that the duration of effect is not particularly long. Thus, 
even if given only at bedtime, within 2-3 h the potency of 
the medication will have been eliminated. 
 I  is still important to keep in mind that vagalytics can
play a role in asthma. That is, if the patient is having diffi-
culty during the sleep-related hours and commonly 
awakens without experiencing benefit from other inter-
ventions then one may strongly consider the use of an 
agent such as ipratropium bromide at the time of these 
awakenings during the middle of the night.
CONCLUSION 
There is no doubt that many pathophysiologic conditions 
change over a 24-hour period and thus therapy needs to 
b  directed at these changes. In particular, asthma has 
been one of the better studied disease processes in 
regard to circadian changes in pathophysiology.50 As we 
continue to learn more about circadian changes, better 
approaches to treating the disease with the same med-
ications will emerge. It hould be remembered that many
asthmatics do not perceive the degree of bronchocon-
striction that they have. This was brought forth in 
Margaret Turner-Warwick's epidemiological study in that 
le s than one-half of the asthmatic individuals who had 
problems with their asthma every night describe their 
asthma as being severe.2 The majority stated they either 
had mild or moderate asthma. Therefore, it is important
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that we use objective criteria such as peak flow meters in 
determining an individual patient's day-to-night changes 
in lung function. Then, any therapeutic intervention can 
be objectively determined at home with both the patient 
and physician gaining knowledge about the ongoing 
asthmatic process.
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